Will Guerrant Email & Phone Number

Fort Lauderdale, FL, US

Fort Lauderdale, FL, US

• Led the coordination, execution and relationship management of multiple partnered projects with large Pharma.
• Managed project functions including deliverables, review of budgets, IP and legal communications, and proposals.
• Regularly coordinated meetings for discussions, exchange of updates and determination of new goals.
• Presented alliance developments, trends and future targets with senior management.
• Collaborated with multifunctional teams across the partnership to advance projects and ensure decisions and action items are clearly documented and tracked to completion.
• Evaluated partner concerns, resolved conflicts and recommended changes to accommodate needs.

Miami, Florida

• Advanced multiple oncology projects from target discovery to lead development, leveraging deep insights into cellular and pathway mechanisms driving multiple cancers.
• Performed biochemical and cell-based high throughput screening as well as mechanism of action studies and target engagement assays to drive research programs from discovery to go/no go decision points.
• Researched, developed and implemented multiple new assay types to support discovery efforts.
• Composed and submitted multiple research grant proposals to the National Institutes of Health (NIH) SBIR program resulting in $2.3M in awards over 3 years.
• Engaged, coordinated, and managed outsourced studies supporting preclinical development through study design and planning, budgeting, supply logistics, troubleshooting, data review and analysis.
• Regularly presented and communicated research program progress to internal and external stakeholders to aid in decision making.

• Designed and executed high-throughput screens to identify preferential small molecule inhibitors of NF2-null Schwann cells in three dimensional (3D) tumor spheroid assay format vs. 2D cell proliferation assay format.
• Implemented assays for validation of the targets and mechanism of action of lead small molecule inhibitors of the Hippo-YAP pathway identified in ultra high-throughput drug discovery campaigns.
• Characterized the oncogenic dependency of NF2-null Schwann cells and xenograft tumors to the YAP transcriptional coactivator using transcriptional profiling, molecular biology, and biochemistry.
• Executed mechanism of action studies for 3D tumor spheroid-specific inhibitors of mutant KRAS.

Greater Atlanta Area

• Designed and performed research specifically relating to profiling new histone deacetylase (HDAC) inhibitors for use in various malignancies, as well as for new uses in infectious diseases.
• Evaluated novel small molecule histone deacetylase (HDAC) inhibitors for potency and isoform selectivity against cancer and normal cell lines.
• Validated the activity and sub-cellular localization of bifunctional HDAC inhibitors.
• Determined the bioavailability (ADME) of lung-targeted HDAC inhibitors.

Greater Atlanta Area

Instructor for teaching labs of General Chemistry, Inorganic Chemistry, and Synthetic Chemistry I & II.

Doctor Of Philosophy (Ph.D.), Biochemistry

Bachelor Of Science (B.S.), Biochemistry And Molecular Biology